Berjis, Abdulla http://orcid.org/0009-0007-7660-5611
Muthumani, Deeksha
Aguilar, Oscar A.
Pomp, Oz
Johnson, Omar
Finck, Amanda V. http://orcid.org/0000-0001-9595-8470
Engel, Nils W.
Chen, Linhui
Plachta, Nicolas http://orcid.org/0000-0002-5035-7425
Scholler, John
Lanier, Lewis L. http://orcid.org/0000-0003-1308-3952
June, Carl H. http://orcid.org/0000-0003-0241-3557
Sheppard, Neil C. http://orcid.org/0000-0002-9551-9491
Article History
Received: 7 September 2023
Accepted: 4 April 2024
First Online: 10 May 2024
Competing interests
: A.B. and N.C.S. have submitted a Patent application covering aspects of this work. C.H.J. has received grant support from Novartis, and has patents related to CAR-Therapy with royalties paid from Novartis to the University of Pennsylvania. C.H.J. is also a scientific co-founder and holds equity in BlueWhale Bio, Capstan Therapeutics and Tmunity Therapeutics. He serves on the board of AC Immune and is a scientific advisor Alaunos, BluesphereBio, Cabaletta, Carisma, Cartography, Cellares, Cellcarta, Celldex, Danaher, Decheng, ImmuneSensor, Poseida, Verismo, Viracta, and WIRB-Copernicus group. L.L.L. is an advisor to Catamaran, Cullinan Oncology, Dragonfly, DrenBio, Edity, GV20, IMIDomics, InnDura Therapeutics, Innovent, Nkarta, oNKo-innate, Obsidian Therapeutics, and SBI Biotech. N.C.S. holds equity in Tmunity Therapeutics and BlueWhale Bio. The remaining authors declare no competing interests.